Atara Biotherapeutics, Inc. (ATRA)

Market Cap	40.43M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
Shares Out	5.86M
EPS (ttm)	-11.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,958
Open	6.65
Previous Close	6.62
Day's Range	6.65 - 6.90
52-Week Range	5.40 - 20.83
Beta	0.49
Analysts	Buy
Price Target	25.70 (+272.46%)
Earnings Date	Mar 7, 2025

About ATRA

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as we...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2014
• Employees: 153
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRA
• Website: https://www.atarabio.com

Financial Performance

In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is $25.7, which is an increase of 272.46% from the latest price.

Price Target

$25.7

(272.46% upside)

Analyst Consensus: Buy